Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $145 from $135 and keeps an Overweight rating on the shares. The firm notes Glaukos reported Q3 sales beating consensus, driven by iDose and OUS MIGS. Management raised sales guidance by $5M at the midpoint, or the magnitude of the beat. Wells sees good momentum for iDose into Q4 and 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS: